Axsome Therapeutics Files 8-K
Ticker: AXSM · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1579428
| Field | Detail |
|---|---|
| Company | Axsome Therapeutics, INC. (AXSM) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K, mostly standard financial updates.
AI Summary
On March 25, 2024, Axsome Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a specific material event. No new financial figures or significant business developments were detailed in the provided excerpt.
Why It Matters
This filing serves as a standard disclosure for Axsome Therapeutics, Inc., providing updates on financial statements and exhibits to the SEC.
Risk Assessment
Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, with no immediate indication of significant new risks or material adverse events.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- March 25, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Axsome Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of March 25, 2024.
What is the exact name of the company filing this report?
The exact name of the company is Axsome Therapeutics, Inc.
On what date was this report filed or effective?
The report was filed as of March 25, 2024, and the date of the earliest event reported is also March 25, 2024.
What is the state of incorporation for Axsome Therapeutics, Inc.?
Axsome Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Axsome Therapeutics, Inc.?
The principal executive offices are located at One World Trade Center, 22nd Floor, New York, New York, 10007.
Filing Stats: 469 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-03-25 09:02:44
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20240325.htm (8-K) — 40KB
- axsm-ex99_1.htm (EX-99.1) — 54KB
- axsm-ex99_2.htm (EX-99.2) — 24KB
- img36028404_0.jpg (GRAPHIC) — 22KB
- axsm-ex99_2s1.jpg (GRAPHIC) — 174KB
- axsm-ex99_2s2.jpg (GRAPHIC) — 671KB
- axsm-ex99_2s3.jpg (GRAPHIC) — 234KB
- axsm-ex99_2s4.jpg (GRAPHIC) — 448KB
- axsm-ex99_2s5.jpg (GRAPHIC) — 460KB
- axsm-ex99_2s6.jpg (GRAPHIC) — 411KB
- axsm-ex99_2s7.jpg (GRAPHIC) — 186KB
- axsm-ex99_2s8.jpg (GRAPHIC) — 420KB
- axsm-ex99_2s9.jpg (GRAPHIC) — 317KB
- axsm-ex99_2s10.jpg (GRAPHIC) — 248KB
- axsm-ex99_2s11.jpg (GRAPHIC) — 243KB
- axsm-ex99_2s12.jpg (GRAPHIC) — 338KB
- axsm-ex99_2s13.jpg (GRAPHIC) — 279KB
- axsm-ex99_2s14.jpg (GRAPHIC) — 329KB
- axsm-ex99_2s15.jpg (GRAPHIC) — 206KB
- axsm-ex99_2s16.jpg (GRAPHIC) — 250KB
- axsm-ex99_2s17.jpg (GRAPHIC) — 189KB
- axsm-ex99_2s18.jpg (GRAPHIC) — 409KB
- axsm-ex99_2s19.jpg (GRAPHIC) — 318KB
- axsm-ex99_2s20.jpg (GRAPHIC) — 299KB
- axsm-ex99_2s21.jpg (GRAPHIC) — 317KB
- axsm-ex99_2s22.jpg (GRAPHIC) — 312KB
- axsm-ex99_2s23.jpg (GRAPHIC) — 500KB
- axsm-ex99_2s24.jpg (GRAPHIC) — 120KB
- axsm-ex99_2s25.jpg (GRAPHIC) — 174KB
- 0000950170-24-035655.txt ( ) — 11086KB
- axsm-20240325.xsd (EX-101.SCH) — 23KB
- axsm-20240325_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On March 25, 2024, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing the results of its SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy (the "SYMPHONY Trial") and will post a presentation regarding the SYMPHONY Trial on its website. The full text of the press release is filed as Exhibit 99.1 hereto, and a copy of the presentation is filed as Exhibit 99.2 hereto, and in each instance is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 25, 2024. 99.2 SYMPHONY Presentation dated March 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: March 25, 2024 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer